| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1030048072 |
| P356 | DOI | 10.1038/NATURE13589 |
| P932 | PMC publication ID | 4199937 |
| P698 | PubMed publication ID | 25119044 |
| P5875 | ResearchGate publication ID | 264796238 |
| P50 | author | Tyler Jacks | Q7860044 |
| Nikhil S. Joshi | Q42063239 | ||
| Tuomas Tammela | Q74796250 | ||
| Wen Xue | Q76388685 | ||
| P2093 | author name string | Daniel G Anderson | |
| Feng Zhang | |||
| Phillip A Sharp | |||
| Roderick Bronson | |||
| Hao Yin | |||
| Thales Papagiannakopoulos | |||
| Sidi Chen | |||
| Wenxin Cai | |||
| Denise G Crowley | |||
| Gillian Yang | |||
| P2860 | cites work | Cas9 as a versatile tool for engineering biology | Q24564294 |
| RNA-guided human genome engineering via Cas9 | Q24598394 | ||
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach | Q24633776 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering | Q29547524 | ||
| The functions and regulation of the PTEN tumour suppressor | Q29615536 | ||
| CRISPR-Cas systems for editing, regulating and targeting genomes | Q29615781 | ||
| CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering | Q29615783 | ||
| Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity | Q29615792 | ||
| DNA targeting specificity of RNA-guided Cas9 nucleases | Q29615793 | ||
| High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells | Q29616045 | ||
| WNT and beta-catenin signalling: diseases and therapies | Q29616159 | ||
| Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas | Q29616243 | ||
| Global microRNA depletion suppresses tumor angiogenesis. | Q33671775 | ||
| Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. | Q34040385 | ||
| Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas | Q34380511 | ||
| Stage-specific sensitivity to p53 restoration during lung cancer progression. | Q34412341 | ||
| Cancer modeling in the modern era: progress and challenges | Q34520417 | ||
| Correction of a genetic disease in mouse via use of CRISPR-Cas9. | Q34658184 | ||
| Distinct pathways of genomic progression to benign and malignant tumors of the liver. | Q35970966 | ||
| Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected] | Q36604703 | ||
| Repurposing CRISPR/Cas9 for in situ functional assays. | Q37388903 | ||
| One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering | Q37651840 | ||
| Stable RNA interference rules for silencing | Q38173633 | ||
| Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma | Q38256553 | ||
| Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. | Q39028341 | ||
| Generation of gene-modified mice via Cas9/RNA-mediated gene targeting | Q43179830 | ||
| Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. | Q45861628 | ||
| Heritable gene targeting in the mouse and rat using a CRISPR-Cas system. | Q47822814 | ||
| Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems | Q52422824 | ||
| Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation | Q52621794 | ||
| Exome sequencing of liver fluke-associated cholangiocarcinoma | Q84073724 | ||
| P433 | issue | 7522 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | CRISPR | Q412563 |
| P304 | page(s) | 380-384 | |
| P577 | publication date | 2014-08-06 | |
| P1433 | published in | Nature | Q180445 |
| P1476 | title | CRISPR-mediated direct mutation of cancer genes in the mouse liver | |
| P478 | volume | 514 |
| Q42605129 | "CRISPR" validation of recessive brain cancer genes in vivo |
| Q57174394 | A Herpes Simplex Virus Thymidine Kinase-Induced Mouse Model of Hepatocellular Carcinoma Associated with Up-Regulated Immune-Inflammatory-Related Signals |
| Q55030506 | A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model. |
| Q38684805 | A Novel Rat Model of Nonalcoholic Fatty Liver Disease Constructed Through CRISPR/Cas-Based Hydrodynamic Injection |
| Q38517896 | A Perspective on the Future of High-Throughput RNAi Screening: Will CRISPR Cut Out the Competition or Can RNAi Help Guide the Way? |
| Q41736028 | A co-clinical platform to accelerate cancer treatment optimization. |
| Q46340316 | A convenient method to pre-screen candidate guide RNAs for CRISPR/Cas9 gene editing by NHEJ-mediated integration of a 'self-cleaving' GFP-expression plasmid. |
| Q35237040 | A genome-wide analysis of Cas9 binding specificity using ChIP-seq and targeted sequence capture. |
| Q36512258 | A non-inheritable maternal Cas9-based multiple-gene editing system in mice |
| Q40191175 | A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo |
| Q38616274 | A simple method based on Sanger sequencing and MS Word wildcard searching to identify Cas9-induced frameshift mutations |
| Q35408740 | A versatile modular vector system for rapid combinatorial mammalian genetics |
| Q35734029 | A versatile reporter system for CRISPR-mediated chromosomal rearrangements. |
| Q35871626 | Adenovirus-Mediated Somatic Genome Editing of Pten by CRISPR/Cas9 in Mouse Liver in Spite of Cas9-Specific Immune Responses. |
| Q26852489 | Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference |
| Q58324031 | All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo |
| Q44620413 | An in vivo transfection system for inducible gene expression and gene silencing in murine hepatocytes |
| Q26781761 | Animal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under Development |
| Q26783442 | Application Progress of CRISPR/Cas9 System for Gene Editing in Tumor Research |
| Q38947491 | Applications of CRISPR Genome Engineering in Cell Biology |
| Q38708498 | Applications of CRISPR genome editing technology in drug target identification and validation |
| Q34539796 | Applications of CRISPR technologies in research and beyond |
| Q34669857 | Applications of CRISPR-Cas9 mediated genome engineering |
| Q91866605 | Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy |
| Q34479139 | Applications of the CRISPR-Cas9 system in cancer biology |
| Q38858314 | Applications of the CRISPR/Cas9 system in murine cancer modeling |
| Q38831318 | Approaches to Inactivate Genes in Zebrafish |
| Q90747737 | Arid1a Loss Drives Nonalcoholic Steatohepatitis in Mice Through Epigenetic Dysregulation of Hepatic Lipogenesis and Fatty Acid Oxidation |
| Q64996715 | Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice. |
| Q92142962 | Base editing the mammalian genome |
| Q26775746 | Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation |
| Q36719581 | Biallelic editing of a lamprey genome using the CRISPR/Cas9 system |
| Q26753206 | Brain tumor modeling using the CRISPR/Cas9 system: state of the art and view to the future |
| Q87985442 | CRISPR Editing in Biological and Biomedical Investigation |
| Q40639390 | CRISPR mediated somatic cell genome engineering in the chicken |
| Q55383943 | CRISPR therapeutic tools for complex genetic disorders and cancer (Review). |
| Q39014648 | CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes |
| Q60915920 | CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics |
| Q27339934 | CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation |
| Q30607892 | CRISPR-Cas9 knockin mice for genome editing and cancer modeling |
| Q38516454 | CRISPR-Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies |
| Q38822073 | CRISPR-Cas9 technology and its application in haematological disorders |
| Q38848400 | CRISPR-Cas9 technology: applications and human disease modelling |
| Q36143201 | CRISPR-Cas9-mediated gene knockout in primary human airway epithelial cells reveals a proinflammatory role for MUC18. |
| Q36149464 | CRISPR-Cas9-mediated genome editing and guide RNA design |
| Q26782773 | CRISPR-Cas9: A Revolutionary Tool for Cancer Modelling |
| Q38364993 | CRISPR-Cas9: a new and promising player in gene therapy |
| Q49477344 | CRISPR-Cas9: a promising genetic engineering approach in cancer research |
| Q37559174 | CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells |
| Q28066263 | CRISPR-Cas9: from Genome Editing to Cancer Research |
| Q64085639 | CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool |
| Q38588821 | CRISPR-Cas: From the Bacterial Adaptive Immune System to a Versatile Tool for Genome Engineering |
| Q91142488 | CRISPR-Cas: a tool for cancer research and therapeutics |
| Q37054587 | CRISPR-Mediated VHL Knockout Generates an Improved Model for Metastatic Renal Cell Carcinoma |
| Q64039535 | CRISPR-SONIC: targeted somatic oncogene knock-in enables rapid in vivo cancer modeling |
| Q58760448 | CRISPR-delivery particles targeting nuclear receptor-interacting protein 1 () in adipose cells to enhance energy expenditure |
| Q35065772 | CRISPR-engineered mosaicism rapidly reveals that loss of Kcnj13 function in mice mimics human disease phenotypes |
| Q92217305 | CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer |
| Q92407854 | CRISPR/Cas9 Delivery Mediated with Hydroxyl-Rich Nanosystems for Gene Editing in Aorta |
| Q39176453 | CRISPR/Cas9 editing of the genome for cancer modeling |
| Q38642367 | CRISPR/Cas9 in the Chicken Embryo |
| Q34499647 | CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice |
| Q26744172 | CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases |
| Q38721201 | CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome |
| Q52427794 | CRISPR/Cas9-based Pten knock-out and Sleeping Beauty Transposon-mediated Nras knock-in induces hepatocellular carcinoma and hepatic lipid accumulation in mice |
| Q42176221 | CRISPR/Cas9-mediated genome editing induces exon skipping by alternative splicing or exon deletion |
| Q33765935 | CRISPR/Cas9-mediated p53 and Pten dual mutation accelerates hepatocarcinogenesis in adult hepatitis B virus transgenic mice |
| Q98224208 | CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity |
| Q33772342 | CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery |
| Q33632925 | CRISPR/Cas9: Transcending the Reality of Genome Editing |
| Q39294371 | CRISPR/Cas9: at the cutting edge of hepatology. |
| Q38614582 | CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer |
| Q55263970 | CRISPR/Cas9: the Jedi against the dark empire of diseases. |
| Q39627059 | CRISPR: a versatile tool for both forward and reverse genetics research. |
| Q88513875 | Cancer CRISPR Screens In Vivo |
| Q90282026 | Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours |
| Q91272447 | Cancer therapy with a CRISPR-assisted telomerase-activating gene expression system |
| Q55333943 | Cell Line Techniques and Gene Editing Tools for Antibody Production: A Review. |
| Q86994509 | Cell biology: delivering tough cargo into cells |
| Q37264419 | Co-incident insertion enables high efficiency genome engineering in mouse embryonic stem cells. |
| Q46571818 | Combinatorial genetics in liver repopulation and carcinogenesis with a novel in vivo CRISPR activation platform. |
| Q38626061 | Combining CRISPR/Cas9 and rAAV Templates for Efficient Gene Editing |
| Q38438854 | Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma |
| Q38622601 | Controlling transcription in human pluripotent stem cells using CRISPR-effectors. |
| Q39051110 | Cornerstones of CRISPR-Cas in drug discovery and therapy |
| Q92845907 | Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases |
| Q47340278 | Cre-dependent Cas9-expressing pigs enable efficient in vivo genome editing |
| Q38682882 | Creating and evaluating accurate CRISPR-Cas9 scalpels for genomic surgery |
| Q38859113 | CrisprGE: a central hub of CRISPR/Cas-based genome editing |
| Q102134513 | Critical cancer vulnerabilities identified by unbiased CRISPR/Cas9 screens inform on efficient cancer Immunotherapy |
| Q52423208 | Cutting short the path to murine liver cancer models |
| Q51603184 | DNA Breaks and End Resection Measured Genome-wide by End Sequencing. |
| Q38676047 | De Novo Gene Expression Reconstruction in Space. |
| Q97681838 | Defining relative mutational difficulty to understand cancer formation |
| Q56610090 | Delivering CRISPR: a review of the challenges and approaches |
| Q40040519 | Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications |
| Q39197557 | Delivery technologies for genome editing |
| Q35611388 | Detection of Tumor Suppressor Genes in Cancer Development by a Novel shRNA-Based Method |
| Q42247800 | Developing a Novel Two-Dimensional Culture System to Enrich Human Prostate Luminal Progenitors that Can Function as a Cell of Origin for Prostate Cancer |
| Q34045952 | Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma |
| Q97646316 | Development of a Self-Restricting CRISPR-Cas9 System to Reduce Off-Target Effects |
| Q38669948 | Developmental history and application of CRISPR in human disease |
| Q36922232 | Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. |
| Q48303103 | Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Gene Editing. |
| Q59355395 | Effects of HPV Pseudotype Virus in Cutting E6 Gene Selectively in SiHa Cells |
| Q35476162 | Efficient CRISPR-rAAV engineering of endogenous genes to study protein function by allele-specific RNAi |
| Q26765901 | Emerging Technologies to Create Inducible and Genetically Defined Porcine Cancer Models |
| Q38378499 | Engineering Stem Cells for Biomedical Applications. |
| Q28469478 | Enhancing Targeted Genomic DNA Editing in Chicken Cells Using the CRISPR/Cas9 System |
| Q39115885 | Epigenetic regulation of the glucose transporter gene Slc2a1 by β-hydroxybutyrate underlies preferential glucose supply to the brain of fasted mice |
| Q26861350 | Epigenome engineering in cancer: fairytale or a realistic path to the clinic? |
| Q37694875 | Establishment of mitochondrial pyruvate carrier 1 (MPC1) gene knockout mice with preliminary gene function analyses |
| Q47578688 | Expanding the CRISPR/Cas9 toolkit for Pichia pastoris with efficient donor integration and alternative resistance markers |
| Q33583723 | Expressed Structurally-stable Inverted Duplicates in Mammalian Genomes as Functional Noncoding Elements |
| Q92778104 | Fabrication and characterization of PLGA nanoparticles encapsulating large CRISPR-Cas9 plasmid |
| Q89865844 | Ferroptosis driven by radical oxidation of n-6 polyunsaturated fatty acids mediates acetaminophen-induced acute liver failure |
| Q35998475 | Fibroblast Growth Factor Signaling Controls Liver Size in Mice With Humanized Livers |
| Q60915307 | Fluorescent labeling of CRISPR/Cas9 RNP for gene knockout in HSPCs and iPSCs reveals an essential role for GADD45b in stress response |
| Q64102183 | Functional Diversity of p53 in Human and Wild Animals |
| Q64053269 | Functional role of SGK3 in PI3K/Pten driven liver tumor development |
| Q26781848 | GEMMs as preclinical models for testing pancreatic cancer therapies |
| Q47134153 | Gene editing of the extra domain A positive fibronectin in various tumors, amplified the effects of CRISPR/Cas system on the inhibition of tumor progression |
| Q38749884 | Gene editing technology as an approach to the treatment of liver diseases |
| Q33899910 | Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma |
| Q35956834 | Generation of cell-type-specific gene mutations by expressing the sgRNA of the CRISPR system from the RNA polymerase II promoters. |
| Q88016594 | Generation of genetically modified mice using CRISPR/Cas9 and haploid embryonic stem cell systems |
| Q41775168 | Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis |
| Q28649502 | Genetic manipulation of reptilian embryos: toward an understanding of cortical development and evolution |
| Q92154219 | Genetically Engineered Mouse Models for Liver Cancer |
| Q28079323 | Genetically engineered mouse models in oncology research and cancer medicine |
| Q26772108 | Genome Editing and Its Applications in Model Organisms |
| Q45875380 | Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid via a Gold Nanocluster/Lipid Core-Shell Nanocarrier |
| Q28252298 | Genome editing. The new frontier of genome engineering with CRISPR-Cas9 |
| Q36221012 | Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice. |
| Q39711118 | Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting |
| Q44169862 | Germline Cas9 expression yields highly efficient genome engineering in a major worldwide disease vector, Aedes aegypti. |
| Q45871734 | Glia-specific enhancers and chromatin structure regulate NFIA expression and glioma tumorigenesis |
| Q57833109 | Global Approaches to Understanding Protein Kinase Functions |
| Q57810095 | Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR/Cas9-mediated genome editing |
| Q48318594 | Hepatocyte-generated 27-hydroxycholesterol promotes the growth of melanoma by activation of estrogen receptor alpha. |
| Q35225214 | Heritable CRISPR/Cas9-mediated genome editing in the yellow fever mosquito, Aedes aegypti |
| Q47594697 | High-Throughput Approaches to Pinpoint Function within the Noncoding Genome |
| Q37017352 | High-Throughput, High-Resolution Mapping of Protein Localization in Mammalian Brain by In Vivo Genome Editing. |
| Q48149827 | High-efficiency non-mosaic CRISPR-mediated knock-in and indel mutation in F0 Xenopus |
| Q63406982 | How to create state-of-the-art genetic model systems: strategies for optimal CRISPR-mediated genome editing |
| Q42594611 | IDH mutations in liver cell plasticity and biliary cancer |
| Q45864365 | Identification of diverse astrocyte populations and their malignant analogs. |
| Q90059594 | Imaging endogenous synaptic proteins in primary neurons at single-cell resolution using CRISPR/Cas9 |
| Q26748886 | In Vivo Delivery Systems for Therapeutic Genome Editing |
| Q52431419 | In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis |
| Q38920337 | In vivo and in vitro disease modeling with CRISPR/Cas9. |
| Q38804017 | In vivo blunt-end cloning through CRISPR/Cas9-facilitated non-homologous end-joining |
| Q97418767 | In vivo functional screening for systems-level integrative cancer genomics |
| Q97438364 | In vivo gene delivery mediated by non-viral vectors for cancer therapy |
| Q37270331 | In vivo genetic dissection of tumor growth and the Warburg effect |
| Q52431137 | In vivo genome editing partially restores alpha1-antitrypsin in a murine model of AAT deficiency. |
| Q52363995 | In vivo genome editing thrives with diversified CRISPR technologies |
| Q35820051 | In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9 |
| Q34463380 | Inducible in vivo genome editing with CRISPR-Cas9 |
| Q89872238 | Insights into the origin of intrahepatic cholangiocarcinoma from mouse models |
| Q60342834 | Intracellular Delivery by Membrane Disruption: Mechanisms, Strategies, and Concepts |
| Q28085748 | Liver-targeted gene therapy: Approaches and challenges |
| Q90384631 | Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses |
| Q33715367 | Long-Term Assessment of AAV-Mediated Zinc Finger Nuclease Expression in the Mouse Brain. |
| Q50176288 | Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway |
| Q26771497 | Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome |
| Q52430587 | Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening |
| Q38598073 | Modeling Disease In Vivo With CRISPR/Cas9. |
| Q36772356 | Modeling Smith-Lemli-Opitz syndrome with induced pluripotent stem cells reveals a causal role for Wnt/β-catenin defects in neuronal cholesterol synthesis phenotypes |
| Q45858962 | Modeling and correction of structural variations in patient-derived iPSCs using CRISPR/Cas9. |
| Q52423411 | Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids |
| Q37051766 | Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland |
| Q39328610 | Modeling the process of human tumorigenesis. |
| Q39106522 | Modern Genome Editing Technologies in Huntington's Disease Research |
| Q89108940 | Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research |
| Q96171845 | Multidimensional imaging of liver injury repair in mice reveals fundamental role of the ductular reaction |
| Q38707232 | Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice |
| Q88540277 | Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing |
| Q38690435 | Nanoscale bio-platforms for living cell interrogation: current status and future perspectives |
| Q40682768 | Neoalbaconol inhibits cell growth of human cholangiocarcinoma cells by up-regulating PTEN. |
| Q38782167 | Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. |
| Q39319380 | Non-viral and viral delivery systems for CRISPR-Cas9 technology in the biomedical field |
| Q52431943 | Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities |
| Q53662280 | Nonadditive Effects of Repetitive Administration of Lipoplexes in Immunocompetent Mice |
| Q54204520 | Novel Method of Plasmid DNA Delivery to Mouse Bladder Urothelium by Electroporation |
| Q33907588 | Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. |
| Q28078150 | Patterns of CRISPR/Cas9 activity in plants, animals and microbes |
| Q42576451 | Porcine cancer models for translational oncology |
| Q34480103 | Precision cancer mouse models through genome editing with CRISPR-Cas9. |
| Q89967414 | Prioritizing Gene Cascading Paths to Model Colorectal Cancer Through Engineered Organoids |
| Q64389145 | Programmable DNA repair with CRISPRa/i enhanced homology-directed repair efficiency with a single Cas9 |
| Q60912966 | Programmable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech |
| Q99417440 | RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges |
| Q50803353 | RNA-binding protein CUGBP1 regulates insulin secretion via activation of phosphodiesterase 3B in mice. |
| Q90191120 | Rapid Generation of Somatic Mouse Mosaics with Locus-Specific, Stably Integrated Transgenic Elements |
| Q37661378 | Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization |
| Q34938584 | Rapid modelling of cooperating genetic events in cancer through somatic genome editing |
| Q36273681 | Rapid tumor induction in zebrafish by TALEN-mediated somatic inactivation of the retinoblastoma1 tumor suppressor rb1 |
| Q58769194 | Rationally-engineered reproductive barriers using CRISPR & CRISPRa: an evaluation of the synthetic species concept in Drosophila melanogaster |
| Q92090098 | Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway |
| Q38679054 | Recent Advances in CRISPR-Cas9 Genome Editing Technology for Biological and Biomedical Investigations |
| Q35146211 | Regenerative medicine: targeted genome editing in vivo |
| Q61798987 | Restriction of hepatitis B virus replication by c-Abl-induced proteasomal degradation of the viral polymerase |
| Q50479880 | Screening out irrelevant cell-based models of disease |
| Q47965742 | Segmentation of digitized histological sections for quantification of the muscularized vasculature in the mouse hind limb |
| Q91595714 | Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing |
| Q41957741 | Single tumor-initiating cells evade immune clearance by recruiting type II macrophages |
| Q35742331 | Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling |
| Q38926441 | Somatic Engineering of Oncogenic Chromosomal Rearrangements: A Perspective |
| Q40609800 | Somatic Genome Editing Goes Viral |
| Q90158851 | Somatic Liver Knockout (SLiK): A Quick and Efficient Way to Generate Liver-Specific Knockout Mice Using Multiplex CRISPR/Cas9 Gene Editing |
| Q52321854 | Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling |
| Q26747309 | Somatic mutations in disorders with disrupted brain connectivity |
| Q36896794 | Spatiotemporal control of estrogen-responsive transcription in ERα-positive breast cancer cells |
| Q47572600 | Stabilization of the c-Myc Protein by CAMKIIγ Promotes T Cell Lymphoma |
| Q28079111 | Survival and Evolution of CRISPR-Cas System in Prokaryotes and Its Applications |
| Q38367820 | Synthetic epigenetics-towards intelligent control of epigenetic states and cell identity |
| Q37733938 | Synthetically controlling dendrimer flexibility improves delivery of large plasmid DNA. |
| Q50891398 | Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma |
| Q96765525 | Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing |
| Q54979175 | Targeted Delivery of CRISPR/Cas9-Mediated Cancer Gene Therapy via Liposome-Templated Hydrogel Nanoparticles. |
| Q37293184 | Targeting ABCB1-mediated tumor multidrug resistance by CRISPR/Cas9-based genome editing |
| Q92117784 | Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects |
| Q64095013 | Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance |
| Q26824997 | The CRISPR revolution and its impact on cancer research |
| Q28085767 | The CRISPR system can correct or modify the expression of genes responsible for hereditary diseases |
| Q39720539 | The Clustered, Regularly Interspaced, Short Palindromic Repeats-associated Endonuclease 9 (CRISPR/Cas9)-created MDM2 T309G Mutation Enhances Vitreous-induced Expression of MDM2 and Proliferation and Survival of Cells |
| Q46262974 | The Future of CRISPR Applications in the Lab, the Clinic and Society |
| Q50048478 | The Polyploid State Plays a Tumor-Suppressive Role in the Liver. |
| Q26765852 | The Rise of CRISPR/Cas for Genome Editing in Stem Cells |
| Q41084526 | The Transcriptional Landscape of p53 Signalling Pathway |
| Q36695546 | The Use of Induced Pluripotent Stem Cells for the Study and Treatment of Liver Diseases. |
| Q38757952 | The application of somatic CRISPR-Cas9 to conditional genome editing in Caenorhabditis elegans |
| Q52426775 | The applications and advances of CRISPR-Cas9 in medical research |
| Q38836751 | The big bang of genome editing technology: development and application of the CRISPR/Cas9 system in disease animal models |
| Q39179722 | The enigmatic oncogene and tumor suppressor-like properties of RAD54B: Insights into genome instability and cancer |
| Q36090852 | The generation and characterization of novel Col1a1FRT-Cre-ER-T2-FRT and Col1a1FRT-STOP-FRT-Cre-ER-T2 mice for sequential mutagenesis |
| Q34043553 | The potential of the combination of CRISPR/Cas9 and pluripotent stem cells to provide human organs from chimaeric pigs |
| Q38840267 | The present and future of genome editing in cancer research |
| Q52423327 | The revolution of the CRISPR is underway |
| Q92917038 | Therapeutic Options for Metastatic Breast Cancer |
| Q33652566 | Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo |
| Q38757432 | Therapeutic genome engineering via CRISPR-Cas systems |
| Q48556291 | Thermo-triggered Release of CRISPR-Cas9 System by Lipid-Encapsulated Gold Nanoparticles for Tumor Therapy |
| Q91861384 | Towards quantitative and multiplexed in vivo functional cancer genomics |
| Q42798174 | Tracing Information Flow from Erk to Target Gene Induction Reveals Mechanisms of Dynamic and Combinatorial Control. |
| Q38878056 | Translational value of mouse models in oncology drug development |
| Q64951901 | Ultrasound microbubble-mediated CRISPR/Cas9 knockout of C-erbB-2 in HEC-1A cells. |
| Q44876995 | Unraveling the potential of CRISPR-Cas9 for gene therapy |
| Q89624062 | Using CRISPR/Cas9 to model human liver disease |
| Q96576712 | Validation of barley 2OGO gene as a functional orthologue of Arabidopsis DMR6 gene in Fusarium head blight susceptibility |
| Q90240699 | Validation of miR-20a as a Tumor Suppressor Gene in Liver Carcinoma Using Hepatocyte-Specific Hyperactive piggyBac Transposons |
| Q38831343 | Zebrafish Rhabdomyosarcoma |
| Q91595896 | Zebrafish patient avatars in cancer biology and precision cancer therapy |
| Q92452023 | [Development of CRISPR technology and its application in bone and cartilage tissue engineering] |
| Q85963380 | [Research advances on gene therapy for hemophilia A] |
| Q96945939 | miR-143 Regulates Lysosomal Enzyme Transport across the Blood-Brain Barrier and Transforms CNS Treatment for Mucopolysaccharidosis Type I |
| Q90726562 | p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression |
| Q36243531 | piggyBac mediates efficient in vivo CRISPR library screening for tumorigenesis in mice |
| Q92665666 | β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma |
Search more.